Under construction – not a live service
Sign in
Taking people in CanadaPhase 2

IVIM & OLINK in Sarcoma

Key facts

Where
Toronto, CanadaSee the site
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT05950594, who can take part

Where in Canada

  • University Health NetworkToronto, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Health Network, Toronto
Trial code
NCT05950594
Record updated
16 March 2026
Original description
The hypoxia > metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).Read full original descriptionShow less

Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas

The hypoxia > metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Inclusion: Age ≥ 18 years; Ability to understand and the willingness to sign a written informed consent document; Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension.

Exclusion: Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI).

ClinicalTrials.gov NCT05950594